## AvMed

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

## **Dry Eye Medications**

**<u>Drug Requested</u>**: (select one from below)

□ Cequa® (cyclosporine ophthalmic solution 0.09%	insert)
☐ <b>Miebo</b> <sup>™</sup> (perfluorohexyloctane ophthalmic solution)	Restasis MultiDose® (cyclosporine ophthalmic emulsion) 0.05%
☐ Tryptyr® (acoltremon ophthalmic solution 0.003%	Tyrvaya® (varenicline solution) nasal spray 0.03 mg
MEMBER & PRESCRIBER INFORM	<b>IATION:</b> Authorization may be delayed if incomplete.
Member Name:	
Member AvMed #:	
Prescriber Name:	
Prescriber Signature:	
Office Contact Name:	
	Fax Number:
NPI #:	
DRUG INFORMATION: Authorization	
Drug Form/Strength:	
	Length of Therapy:
Diagnosis:	
Weight (if applicable):	

## **Quantity Limits:**

- Cequa® and Lacrisert®: 60-unit doses or single-use vials per 30 days
- **Miebo**<sup>™</sup>: 1 bottle (3 mL) per 30 days
- **Restasis MultiDose**®: 1 bottle (5.5 mL) per 30 days
- Tyrvaya®: 2 bottles (1 package of 8.4 mL) per 30 days
- Tryptyr<sup>®</sup>: 60 single-dose vials per 30 days

(Continued on next page)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Member has tried and failed at least 30 days of therapy with BOTH of the following medications:
☐ generic cyclosporine 0.05% ophthalmic emulsion

☐ Xiidra® (lifitegrast ophthalmic solution) 5%

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria. \*\*

\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. \*